Abgenix Announces Initiation of a Phase 2 Clinical Trial of ABX-EGF
in Combination With Chemotherapy in Patients With Colorectal Cancer
09-Jan-2002 -
FREMONT, CA - Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase 2 clinical trial of ABX-EGF in
patients with colorectal cancer. This clinical trial, the fifth Phase 2 study of ABX-EGF and the second for the colorectal cancer
indication, is designed to assess the safety and ...
chemotherapy
clinical trials
colorectal cancer
+3